Patents Assigned to RFE Pharma LLC
  • Publication number: 20170007581
    Abstract: The subject invention provides CAI compounds and formulations thereof, and methods for their use in the localized treatment of non-life threatening diseases. Formulations of CAI compounds of the subject invention include CAI free base and CAI prodrug microcrystallines, microparticles, emulsions, and the like. The subject invention further provides methods for treating non-life threatening diseases using the CAI compounds of the invention (i.e., novel delivery systems and combination therapies), that are effective and are associated with little or no adverse side effects.
    Type: Application
    Filed: September 22, 2016
    Publication date: January 12, 2017
    Applicant: RFE Pharma LLC
    Inventors: Gary Robinson, Gideon Shapiro, Alan J. Franklin, Simona Jurczyk
  • Publication number: 20140154246
    Abstract: The subject invention provides CAI compounds and formulations thereof, and methods for their use in the localized treatment of non-life threatening diseases. Formulations of CAI compounds of the subject invention include CAI free base and CAI prodrug microcrystallines, microparticles, emulsions, and the like. The subject invention further provides methods for treating non-life threatening diseases using the CAI compounds of the invention (i.e., novel delivery systems and combination therapies), that are effective and are associated with little or no adverse side effects.
    Type: Application
    Filed: February 6, 2014
    Publication date: June 5, 2014
    Applicant: RFE Pharma LLC
    Inventors: Gary Robinson, Gideon Shapiro, Alan J. Franklin, Simona Jurczyk
  • Publication number: 20140079694
    Abstract: The subject invention provides CAI compounds and formulations thereof, and methods for their use in the localized treatment of non-life threatening diseases. Formulations of CAI compounds of the subject invention include CAI free base and CAI prodrug microcrystallines, microparticles, emulsions, and the like. The subject invention further provides methods for treating non-life threatening diseases using the CAI compounds of the invention (i.e., novel delivery systems and combination therapies), that are effective and are associated with little or no adverse side effects.
    Type: Application
    Filed: November 19, 2013
    Publication date: March 20, 2014
    Applicant: RFE Pharma LLC
    Inventors: GARY ROBINSON, Gideon Shapiro, Alan J. Franklin, Simona Jurczyk
  • Patent number: 8614235
    Abstract: The subject invention provides CAI compounds and formulations thereof, and methods for their use in the localized treatment of non-life threatening diseases. Formulations of CAI compounds of the subject invention include CAI free base and CAI prodrug microcrystallines, microparticles, emulsions, and the like. The subject invention further provides methods for treating non-life threatening diseases using the CAI compounds of the invention (i.e., novel delivery systems and combination therapies) that are effective and are associated with little or no adverse side effects.
    Type: Grant
    Filed: July 13, 2011
    Date of Patent: December 24, 2013
    Assignee: RFE Pharma LLC
    Inventors: Gary Robinson, Gideon Shapiro, Alan J. Franklin, Simona Jurczyk